logo

For the Inventor, By the Inventor

Ottawa, Canada

William W Ogilvie

This inventor holds 12 USPTO granted patents, plus 2 CIPO patents. Top assignees: Boehringer Ingelheim (Canada) Ltd., Boehringer Ingelheim International Gmbh. Active years: 2001-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: William W Ogilvie. Retrieved from https://idiyas.com/inventor/william-w-ogilvie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12

% Patents Active = 91.7


Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 26(Granted Patents)


Location History:

  • Rosemére, CA (2001)
  • Rosemère, CA (2001)
  • Laval, CA (2006)
  • Ottawa, CA (2004 - 2010)

Company Filing History:

goldMedal11 out of 62 
 
Boehringer Ingelheim (Canada) Ltd.
 patents
silverMedal1 out of 1,561 
 
Boehringer Ingelheim International Gmbh
 patents

Years Active: 2001-2010

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 7807670 - Inhibitors of papilloma virus (2010-10-05),
2. 7528167 - Inhibitors of papilloma virus (2009-05-05),
3. 7273861 - Non-nucleoside reverse transcriptase inhibitors (2007-09-25),
4. 7119099 - Inhibitors of papilloma virus (2006-10-10),
5. 7105510 - Non-nucleoside reverse transcriptase inhibitors (2006-09-12),
6. 6759409 - Inhibitors of papilloma virus (2004-07-06),
7. 6716836 - Non-nucleoside reverse transcriptase inhibitors (2004-04-06),
8. 6706706 - Non-nucleoside reverse transcriptase inhibitors (2004-03-16),
9. 6673791 - Non-nucleoside reverse transcriptase inhibitors (2004-01-06),
10. 6242439 - Azetidinone derivatives for the treatment of HCMV infections (2001-06-05),
11. 6239125 - Azetidinone derivatives for the treatment of HCMV infections (2001-05-29),
12. 6211170 - Azetidinone derivatives for the treatment of HCMV infections (2001-04-03),

Title: The Innovative Contributions of William W. Ogilvie

Introduction

William W. Ogilvie is a notable inventor based in Ottawa, Canada. He has made significant contributions to the field of medical research, particularly in the development of compounds that inhibit the papilloma virus. With a total of 12 patents to his name, Ogilvie's work has the potential to impact public health positively.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Inhibitors of papilloma virus." This patent describes a compound of formula (I) or its enantiomers or diastereoisomers, which can be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention also provides a method for treating or preventing human papilloma virus infection, showcasing Ogilvie's commitment to advancing medical science.

Career Highlights

Ogilvie has worked with prominent companies in the pharmaceutical industry, including Boehringer Ingelheim (Canada) Ltd. and Boehringer Ingelheim International GmbH. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to innovative research.

Collaborations

Some of his notable coworkers include Jeffrey O'Meara and Christiane Yoakim. Their collaborative efforts have further enhanced the research and development of effective treatments for viral infections.

Conclusion

William W. Ogilvie's contributions to the field of medical research and his innovative patents demonstrate his dedication to improving health outcomes. His work continues to inspire future advancements in the fight against viral infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…